Search

Your search keyword '"Shida, Haruka"' showing total 18 results
Start Over Author "Shida, Haruka"
18 results on '"Shida, Haruka"'

1. Early prognostic impact of serum sodium level among out-of-hospital cardiac arrest patients: a nationwide multicentre observational study in Japan (the JAAM-OHCA registry)

Author

Shida, Haruka, Matsuyama, Tasuku, Komukai, Sho, Irisawa, Taro, Yamada, Tomoki, Yoshiya, Kazuhisa, Park, Changhwi, Nishimura, Tetsuro, Ishibe, Takuya, Yagi, Yoshiki, Kiguchi, Takeyuki, Kishimoto, Masafumi, Kim, Sung-Ho, Hayashi, Yasuyuki, Sogabe, Taku, Morooka, Takaya, Sakamoto, Haruko, Suzuki, Keitaro, Nakamura, Fumiko, Nishioka, Norihiro, Okada, Yohei, Matsui, Satoshi, Yoshimura, Satoshi, Kimata, Shunsuke, Kawai, Shunsuke, Makino, Yuto, Iwami, Taku, and Kitamura, Tetsuhisa

Published
2022
Full Text
View/download PDF

4. Effects of Mobilization within 72 h of ICU Admission in Critically Ill Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author

Matsuoka, Ayaka, primary, Yoshihiro, Shodai, additional, Shida, Haruka, additional, Aikawa, Gen, additional, Fujinami, Yoshihisa, additional, Kawamura, Yusuke, additional, Nakanishi, Nobuto, additional, Shimizu, Motohiro, additional, Watanabe, Shinichi, additional, Sugimoto, Kensuke, additional, Taito, Shunsuke, additional, and Inoue, Shigeaki, additional

Published
2023
Full Text
View/download PDF

5. Use of National Database of Health Insurance Claims and Specific Health Checkups for examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in Japan

Author

Shida, Haruka, primary, Kajiyama, Kazuhiro, additional, Sawada, Sono, additional, Ishiguro, Chieko, additional, Kubo, Mikiko, additional, Kimura, Ryota, additional, Hirano, Mai, additional, Komiyama, Noriyuki, additional, Iguchi, Toyotaka, additional, Oniyama, Yukio, additional, and Uyama, Yoshiaki, additional

Published
2023
Full Text
View/download PDF

8. Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

Author

Sawada, Sono, Kajiyama, Kazuhiro, Shida, Haruka, Kimura, Ryota, Nakazato, Yuki, Iguchi, Toyotaka, Oniyama, Yukio, Ishiguro, Chieko, and Uyama, Yoshiaki

Subjects
NATIONAL health insurance, PROPORTIONAL hazards models, CARDIOVASCULAR diseases risk factors, ACUTE coronary syndrome, CEREBRAL hemorrhage, CEREBRAL infarction
Abstract

In the present study, we aimed to investigate the association between urate‐lowering drugs and cardiovascular events, primarily focusing on the risk of febuxostat and topiroxostat when compared with allopurinol in Japan. We conducted an observational study with a cohort design using the National Database of Health Insurance Claims and Specific Health Checkups of Japan, including new urate‐lowering drugs users between August 1, 2010, and March 31, 2018. Exposure and control groups were defined based on the first prescription of urate‐lowering drugs as follows: febuxostat or topiroxostat for exposure groups, allopurinol for the control group, and benzbromarone for the secondary control group. The primary outcome was cardiovascular events, defined as a composite of acute coronary syndrome, cerebral infarction, and cerebral hemorrhage. Hazard ratios were estimated using a Cox proportional hazards model. The number of patients in each exposure and control group was 1,357,671 in the febuxostat group, 83,683 in the topiroxostat group, 1,273,211 in the allopurinol group, and 258,786 in the benzbromarone group. The adjusted hazard ratios for the cardiovascular risk were 0.97 (95% confidence interval [CI]: 0.95–0.98) for febuxostat and 0.84 (95% CI: 0.78–0.90) for topiroxostat groups. The benzbromarone group exhibited similar results. No increased cardiovascular risk was observed with febuxostat or topiroxostat when compared with allopurinol in patients with hyperuricemia in Japan. These results provide real‐world evidence regarding the cardiovascular risk associated with urate‐lowering drugs, indicating that no additional safety‐related regulatory actions are warranted in Japan. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Prehospital cardiopulmonary resuscitation duration and neurological outcome after adult out-of-hospital cardiac arrest by location of arrest

Author

Kishimori, Takefumi, primary, Matsuyama, Tasuku, additional, Kiyohara, Kosuke, additional, Kitamura, Tetsuhisa, additional, Shida, Haruka, additional, Kiguchi, Takeyuki, additional, Nishiyama, Chika, additional, Kobayashi, Daisuke, additional, Okabayashi, Satoe, additional, Shimamoto, Tomonari, additional, Sado, Junya, additional, Kawamura, Takashi, additional, and Iwami, Taku, additional

Published
2020
Full Text
View/download PDF

11. Serum potassium level on hospital arrival and survival after out-of-hospital cardiac arrest: The CRITICAL study in Osaka, Japan

Author

Shida, Haruka, primary, Matsuyama, Tasuku, additional, Iwami, Taku, additional, Okabayashi, Satoe, additional, Yamada, Tomoki, additional, Hayakawa, Koichi, additional, Yoshiya, Kazuhisa, additional, Irisawa, Taro, additional, Noguchi, Kazuo, additional, Nishimura, Tetsuro, additional, Uejima, Toshifumi, additional, Yagi, Yoshiki, additional, Kiguchi, Takeyuki, additional, Kishimoto, Masafumi, additional, Matsuura, Makoto, additional, Hayashi, Yasuyuki, additional, Sogabe, Taku, additional, Morooka, Takaya, additional, Sado, Junya, additional, Kishimori, Takefumi, additional, Kiyohara, Kosuke, additional, Shimazu, Takeshi, additional, Kitamura, Tetsuhisa, additional, and Kawamura, Takashi, additional

Published
2020
Full Text
View/download PDF

13. Public-access automated external defibrillator pad application and favorable neurological outcome after out-of-hospital cardiac arrest in public locations: A prospective population-based propensity score-matched study

Author

Kishimori, Takefumi, primary, Kiguchi, Takeyuki, additional, Kiyohara, Kosuke, additional, Matsuyama, Tasuku, additional, Shida, Haruka, additional, Nishiyama, Chika, additional, Kobayashi, Daisuke, additional, Okabayashi, Satoe, additional, Shimamoto, Tomonari, additional, Hayashida, Sumito, additional, Kitamura, Tetsuhisa, additional, Kawamura, Takashi, additional, and Iwami, Taku, additional

Published
2020
Full Text
View/download PDF

14. Intra-aortic balloon pump and survival with favorable neurological outcome after out-of-hospital cardiac arrest: A multicenter, prospective propensity score-matched study

Author

Kishimori, Takefumi, primary, Matsuyama, Tasuku, additional, Yamada, Tomoki, additional, Hayakawa, Koichi, additional, Yoshiya, Kazuhisa, additional, Irisawa, Taro, additional, Noguchi, Kazuo, additional, Nishimura, Tetsuro, additional, Uejima, Toshifumi, additional, Yagi, Yoshiki, additional, Kiguchi, Takeyuki, additional, Kishimoto, Masafumi, additional, Matsuura, Makoto, additional, Hayashi, Yasuyuki, additional, Sogabe, Taku, additional, Morooka, Takaya, additional, Sado, Junya, additional, Shida, Haruka, additional, Kiyohara, Kosuke, additional, Shimazu, Takeshi, additional, Kawamura, Takashi, additional, Iwami, Taku, additional, and Kitamura, Tetsuhisa, additional

Published
2019
Full Text
View/download PDF

15. Characteristics and outcomes of out-of-hospital cardiac arrest in Japan

Author

Kiyohara, Kosuke, primary, Matsuyama, Tasuku, additional, Nishiyama, Chika, additional, Kitamura, Tetsuhisa, additional, Shimamoto, Tomonari, additional, Kobayashi, Daisuke, additional, Kiguchi, Takeyuki, additional, Okabayashi, Satoe, additional, Sado, Junya, additional, Matsui, Satoshi, additional, Okubo, Masashi, additional, Izawa, Junichi, additional, Kishimori, Takefumi, additional, Shida, Haruka, additional, Kawamura, Takashi, additional, and Iwami, Taku, additional

Published
2019
Full Text
View/download PDF

16. Abstract 183: Public-Access Automated External Defibrillator Pad Application and Favorable Neurological Outcome After Out-of-Hospital Cardiac Arrest in Public Locations; A Prospective Population-Based Propensity-Score Matched Study

Author

Kishimori, Takefumi, primary, Kiguchi, Takeyuki, additional, Kiyohara, Kosuke, additional, Matsuyama, Tasuku, additional, Shida, Haruka, additional, Hayashida, Sumito, additional, Kitamura, Tetsuhisa, additional, Kawamura, Takashi, additional, and Iwami, Taku, additional

Published
2018
Full Text
View/download PDF

18. Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

Author

Sawada S, Kajiyama K, Shida H, Kimura R, Nakazato Y, Iguchi T, Oniyama Y, Ishiguro C, and Uyama Y

Subjects
Humans, Uric Acid, Febuxostat, Allopurinol, Gout Suppressants adverse effects, Benzbromarone adverse effects, Japan epidemiology, Risk Factors, Insurance, Health, Heart Disease Risk Factors, Treatment Outcome, Gout drug therapy, Cardiovascular Diseases epidemiology, Cardiovascular Diseases drug therapy
Abstract

In the present study, we aimed to investigate the association between urate-lowering drugs and cardiovascular events, primarily focusing on the risk of febuxostat and topiroxostat when compared with allopurinol in Japan. We conducted an observational study with a cohort design using the National Database of Health Insurance Claims and Specific Health Checkups of Japan, including new urate-lowering drugs users between August 1, 2010, and March 31, 2018. Exposure and control groups were defined based on the first prescription of urate-lowering drugs as follows: febuxostat or topiroxostat for exposure groups, allopurinol for the control group, and benzbromarone for the secondary control group. The primary outcome was cardiovascular events, defined as a composite of acute coronary syndrome, cerebral infarction, and cerebral hemorrhage. Hazard ratios were estimated using a Cox proportional hazards model. The number of patients in each exposure and control group was 1,357,671 in the febuxostat group, 83,683 in the topiroxostat group, 1,273,211 in the allopurinol group, and 258,786 in the benzbromarone group. The adjusted hazard ratios for the cardiovascular risk were 0.97 (95% confidence interval [CI]: 0.95-0.98) for febuxostat and 0.84 (95% CI: 0.78-0.90) for topiroxostat groups. The benzbromarone group exhibited similar results. No increased cardiovascular risk was observed with febuxostat or topiroxostat when compared with allopurinol in patients with hyperuricemia in Japan. These results provide real-world evidence regarding the cardiovascular risk associated with urate-lowering drugs, indicating that no additional safety-related regulatory actions are warranted in Japan., (© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results